Mechanism
How Benralizumab works
Binds the IL-5 receptor alpha subunit on eosinophils and basophils, leading to antibody-dependent cell-mediated cytotoxicity and near-complete eosinophil depletion.
← Respiratory Pharmacology
BIONBRC High Yield5/5 Importance
Benralizumab Respiratory Pharmacology Guide
Mechanism, indications, adverse effects, kinetics, exam traps, and NBRC-focused guidance for respiratory therapy students and clinicians.
Benralizumab is a monoclonal antibody used for severe eosinophilic asthma. Unlike mepolizumab, which binds IL-5 directly, benralizumab binds the IL-5 receptor and promotes eosinophil depletion. Students should recognize both medications as eosinophilic asthma biologics while understanding their different targets.
Clinical Pharmacology
Understand the medication before memorizing it
Start with mechanism, clinical pearls, onset, peak, duration, and deeper pharmacology explanations so the rest of the page has context.
Clinical Pearl
What to remember
Mepolizumab hits IL-5. Benralizumab hits the IL-5 receptor.
Kinetics
Onset, peak, and duration
1
Onset
Weeks
2
Peak
Variable
3
Duration
Long-term biologic therapy
Clinical Practice
How this medication is used at the bedside
Review common indications, expected adverse effects, contraindications, cautions, and safety issues in a clinically useful order.
Quick facts
- Subclass
- Anti-IL-5 receptor monoclonal antibody
- NBRC importance
- 5/5
- Difficulty
- 4/5
- Brands
- Fasenra
5/5
NBRC importance
9
Study facts
0
Practice questions
2026
Updated
Common indications
- Severe eosinophilic asthma
- Add-on maintenance therapy for eosinophilic asthma
Adverse effects
- Headache
- Injection site reactions
- Pharyngitis
- Fever
Contraindications
- Hypersensitivity to benralizumab or formulation components
Cautions and safety issues
- Not a rescue medication
- Monitor for hypersensitivity reactions
RT & NBRC Mastery
Respiratory therapy exam and bedside mastery
Move from reference knowledge into board-style reasoning, adaptive practice, common distractors, and high-yield clinical scenarios.
NBRC-style question
NBRC-style pharmacology review
A patient scenario involves severe eosinophilic asthma. Which medication concept should the respiratory therapy student recognize?
High-yield answer
Benralizumab = Anti-IL-5R
Interactive practice
The Adaptive Exam Simulator
Use the complete guide on this page to learn the medication, then switch into the adaptive simulator to test yourself with scored practice, missed-concept review, and NBRC-style clinical reasoning.
ClassPractice
MechanismPractice
Clinical usePractice
Adverse effectsPractice
ScenarioPractice
Common Exam Traps
These are the answer choices, mechanisms, or medication classes most commonly confused with this medication on RT school and NBRC-style exams.
- Anti-IgE
- Anti-IL-5
- Anti-IL-4 receptor
- Bronchodilator
- Inhaled corticosteroid
High-Yield Clinical Scenarios
- Severe eosinophilic asthma
- Question distinguishing mepolizumab versus benralizumab
- Biologic target identification
Guidelines
Guideline-based clinical context
Connect medication facts to the larger respiratory care guidelines, disease-state recommendations, and clinical decision frameworks.
Study Tools
Practice, recall, and retention
Use mini cases, flashcards, FAQs, and related concepts to turn the medication page into a high-retention study experience.
Practice Questions
Curated practice preview
Review a concise sample here, then use the adaptive simulator for all 0 board-style and clinical reasoning questions.
Related study paths
Continue building pharmacology mastery
Use this medication page as a reference, then reinforce it with interactive practice and related PulmTools study resources.